Autres langues Revive Therapeutics Ltd Toronto S.E.

Actions

RVV

CA7615161030

Temps Différé Toronto S.E. Autres places de cotation			Varia. 5j.	Varia. 1 janv.
- ^CAD	-.--%		+6,67%	-11,11%

18/04	Revive Therapeutics Ltd. annonce l'acceptation par la FDA de la demande de réunion concernant le produit de diagnostic Long COVID	CI
02/04	Revive Therapeutics Ltd. fournit une mise à jour de l'étude clinique sur la psilocybine pour les troubles liés à l'utilisation de la méthamphétamine	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Revive Therapeutics : Document	17/05
Revive Therapeutics : Document	17/05
FDA Grants Revive Therapeutics Type C Meeting Request For Bucillamine Study to Treat Long COVID	23/04
Revive Therapeutics Brief: Announcing Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID	23/04
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID	23/04
Revive Therapeutics Announced FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	18/04
Revive Therapeutics Brief: Announcing FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	18/04
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	18/04
Revive Therapeutics Ltd. Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	18/04
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	02/04
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	02/04
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	02/04
Revive Therapeutics Ltd. Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	02/04
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	27/03
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	27/03
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	27/03
Revive Therapeutics : Document	20/03
Revive Therapeutics : Document	20/03
Revive Therapeutics to Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID	19/03
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID	19/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Revive Therapeutics Ltd Toronto S.E.

Actions

RVV

CA7615161030

Autres langues

Filtres